Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others), By Delivery Method (Ex-vivo, In-vivo), By End User (Pharmaceutical & Biotechnology Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026
Global genome editing market is expected to reach USD8711.24 million by 2026, growing at double-digit CAGR of 12.73% over the forecast period. Growing research & development activities for the treatment of various chronic diseases and increasing preference for personalized medicine are fueling the market growth of genome editing until 2026.
Genome editing is a way of making specific changes to the DNA of a cell or organism. It could be used to edit the genome of any organism. It uses a type of enzyme called an ‘engineered nuclease’ which cuts the genome in a specific place. After cutting the DNA in a specific place, the cell naturally repairs itself. It finds application in large number of areas, such as mutation, therapeutics, and agriculture biotechnology. Rise in the number of chronic and infectious diseases is likely to expand the scope of genome editing in the coming years.
The global genome editing market is segmented based on technique, application, delivery method, end-user, region and company. Based on technique, the market is segmented into CRISPR, TALENs, Zinc Finger Nucleases and others. CRISPR dominates the market in this segment and is expected to be the fastest growing segment because as it is cheaper and is the most efficient technique among the rest. Based on application, the market is segmented into cell line engineering, animal genetic engineering, plant genetic engineering and others. Among them, the cell line engineering is expected to witness the highest growth rate in the coming years due to increase in the number of people suffering with genetic disorders and rising government funding for stem cell research.
Based on end-user, the global genome editing market is segmented into pharmaceutical & biotechnology companies, clinical research organization and research institutes. Pharmaceutical & biotechnology companies contribute to the largest share of revenue generation for global genome editing market. Growing establishment of biotech and pharma companies in emerging economies and growing usage of gene editing technique in research activities undertaken by them to manufacture and develop drugs for rare diseases are the enablers for the growth of the market.
The major players operating in the global genome editing market are Thermo Fisher Scientific Inc., Homology Medicines, Inc., CRISPR Therapeutics AG, Pfizer Inc., Editas Medicine Inc., Intellia Therapeutics Inc., Cellectis SA, Sangamo Therapeutics Inc., Origene Technologies Inc., Merck & Co Inc., New England Biolabs Inc., Lonza Group AG, Danaher Corporation (Integrated DNA Technologies Inc.), PerkinElmer Inc. (Horizon Discovery Group Plc), Genscript Corp., Oxford Genetics Ltd., Bayer AG, Arcturus Therapeutics Inc, Inscripta Inc., Beam therapeutics Inc. and others. Growing number of research and development is going to drive the genome editing market in the coming years.
Years considered for this report:
Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022– 2026
Objective of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook